Long-Term Peritoneal Indwelling Catheters for Malignant Ascites: A Retrospective Case Series of PleurX and Peritoneal Port

J Palliat Med. 2022 Jul;25(7):1127-1131. doi: 10.1089/jpm.2021.0504. Epub 2022 Mar 23.

Abstract

Objectives: To compare outcomes of PleurX and peritoneal port for malignant ascites. Design: Retrospective review of medical records was conducted. Setting/Subjects: Subjects were consecutive patients receiving PleurX or peritoneal port for malignant ascites in a center in Sydney, Australia. Measurements: Demographic data, complication rates, hospitalization rates, and survival were measured. Results: Sixteen cases were analyzed: 6 had peritoneal port (170 catheter days) and 10 had PleurX (477 catheter days). Complication rates were low with both drainage systems. Cellulitis rate was 33% (1.2 events/100 catheter days) for peritoneal port and 10% (0.2 events/100 catheter days) for PleurX. Hospital admission days were 27 days/100 catheter days for peritoneal port and 5.2 days/100 catheter days for PleurX. Conclusions: Both PleurX and peritoneal port seem feasible options in draining malignant ascites. Further research is needed to ascertain whether there are true differences in cellulitis/admission rates. Patient quality of life, experience, and preference should be included in future studies.

Keywords: ascites; complications; indwelling catheter; malignant.

MeSH terms

  • Ascites* / etiology
  • Ascites* / therapy
  • Catheters, Indwelling / adverse effects
  • Cellulitis / complications
  • Humans
  • Peritoneal Neoplasms* / complications
  • Quality of Life
  • Retrospective Studies